Want to see GENB full AI Analyst Report?
Top Page
Generate Biomedicines, Inc.
(NASDAQ:GENB)
Select Model
Select Model
Rating:49Neutral
Price Target:
$13.50
â–²(8.43% Upside)
Action:Reiterated
Date:06/23/26
The score is primarily weighed down by very weak financial performance: widening losses, substantial and worsening cash burn, and deeply negative equity. Technical indicators are comparatively supportive with positive momentum above key moving averages, but valuation is constrained by negative earnings and no provided dividend yield.
Positive Factors
Top-line growth
Sustained revenue growth demonstrates the company is converting its platform output into commercial or partnered revenue streams. Over a 2-6 month horizon, rising top line suggests improving program validation and market traction that can underpin scaling and future non-dilutive partnerships.
Negative Factors
Worsening cash burn
Very large and increasing cash outflows are a durable constraint: sustained negative operating and free cash flow forces frequent external funding, raises dilution risk, and can divert management focus to financing over execution, increasing execution and continuity risk across months.
Read all positive and negative factors
Positive Factors
Negative Factors
Top-line growth
Sustained revenue growth demonstrates the company is converting its platform output into commercial or partnered revenue streams. Over a 2-6 month horizon, rising top line suggests improving program validation and market traction that can underpin scaling and future non-dilutive partnerships.
Read all positive factors
Generate Biomedicines, Inc. (GENB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.75B
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)0.52
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees312
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding128,192,490
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-1.03
Price to Sales (P/S)19.87
P/FCF Ratio-3.10
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue238.77
Enterprise Value/Gross Profit436.57
Enterprise Value/Ebitda-28.35
Forecast
1Y Price Target
$25.25Price Target Upside102.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Generate Biomedicines, Inc. Business Overview & Revenue Model
Company Description
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modal...
How the Company Makes Money
null...
Generate Biomedicines, Inc. Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 |
|---|---|---|---|
Income Statement | |||
| Total Revenue | 7.22M | 31.89M | 20.46M |
| Gross Profit | 3.95M | 31.89M | 20.46M |
| EBITDA | -60.84M | -208.49M | -163.71M |
| Net Income | -61.45M | -203.15M | -173.77M |
Balance Sheet | |||
| Total Assets | 625.74M | 330.18M | 518.26M |
| Cash, Cash Equivalents and Short-Term Investments | 516.64M | 221.50M | 393.63M |
| Total Debt | 65.57M | 68.53M | 76.97M |
| Total Liabilities | 110.94M | 953.38M | 953.35M |
| Stockholders Equity | 514.80M | -615.97M | -434.52M |
Cash Flow | |||
| Free Cash Flow | -84.17M | -204.13M | -121.20M |
| Operating Cash Flow | -80.39M | -200.62M | -117.75M |
| Investing Cash Flow | -252.43M | 116.77M | -57.73M |
| Financing Cash Flow | 371.39M | 28.06M | 91.33M |
Generate Biomedicines, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.